An obscure and extremely powerful psychedelic drug called 5-MeO-DMT, or BUFO, is drawing intense interest from the pharmaceutical industry, where biotech companies like AtaiBeckley and GH Research are racing to turn it into a commercially available treatment for severe mental health disorders, like depression, anxiety and PTSD.
WSJ took an inside look at how the psychedelic is being used at unregulated clinics in Mexico, and why companies are betting that it could soon turn into a billion dollar blockbuster drug.
Chapters:
0:00 The power of 5-MeO-DMT
1:31 Inside a treatment facility in Mexico
5:36 5-MeO-DMT uses and history
8:10 The psychedelic therapies market
10:46 The race to commercialize psychedelics
14:08 After the treatment in Mexico
WSJ Originals features in-depth reporting, investigations and on-the-ground journalism that uncovers the forces shaping business, politics and the world around us.
#DMT #Psychedlics #WSJ
|
Oil shocks from the war with Iran and th...
Can America stay ahead in artificial int...
The 'Fast Money' traders talk SpaceX's n...
Propagate co-CEO and Fmr NBC Entertainme...
#yahoofinance #business #stockmarket 3...
Ali Ghodsi, Databricks CEO, talks with C...
The CNBC Business News Update with Jill ...
Warren Pies, 3Fourteen Ventures, joins '...
== AlphaSpace by Yahoo Finance: A Profes...
Has the stock market become a casino? W...
As the 2026 FIFA World Cup comes to a cl...
Bloomberg’s Ed Ludlow looks at Chinese s...
Why is Marine Le Pen, the leader of Fran...
WSJ’s David Wainer explains why the late...
Andy Burnham promised to be a 'pro-busin...